the European Medicines Agency (EMEA) has rejected the application of for ATryn, an anti-blod clotting protein derived from the milk of genetically-engineered goats, arguing that it was not yet demonstrated that A Tryn`s benefits are greater than its risks. <a href="http://www.forbes.com/markets/feeds/afx/2006/02/23/afx2550140.html">First drug from transgenic animal fails to get EU approval - Forbes.com</a></p><p><a href="http://www.nytimes.com/2006/02/24/business/worldbusiness/24drug.html">New York Times: Europe Rejects Genetically Engineered Drug</a></p><p><a href="http://www.emea.eu.int/pdfs/human/opinion/QandA_Atryn_6202206en.pdf">EMEA: Questions and Answers on ATryn</a>